Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUWIN durvalumab + tremelimumab with Y-90 SIRT for intermediate-stage hepatocellular carcinoma
2024-513950-32-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Planned start Dec 2020; status: authorised.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-513950-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513950-32-00.